Factor XIII Val34Leu polymorphism and ischaemic stroke in patients with patent foramen ovale

Ewa Wypasek; Ewa Stepien; Monika Pieculewicz; Piotr Podolec; Anetta Undas

doi:10.1160/TH09-03-0144

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 102(06): 1280-1282
DOI: 10.1160/TH09-03-0144

Letters to the Editor

Schattauer GmbH

Factor XIII Val34Leu polymorphism and ischaemic stroke in patients with patent foramen ovale

Ewa Wypasek

¹Institute of Cardiology, Jagiellonian University School of Medicine, Cracow, Poland

²John Paul II Hospital, Cracow, Poland

,

Ewa Stepien

¹Institute of Cardiology, Jagiellonian University School of Medicine, Cracow, Poland

²John Paul II Hospital, Cracow, Poland

,

Monika Pieculewicz

¹Institute of Cardiology, Jagiellonian University School of Medicine, Cracow, Poland

,

Piotr Podolec

¹Institute of Cardiology, Jagiellonian University School of Medicine, Cracow, Poland

,

Anetta Undas

¹Institute of Cardiology, Jagiellonian University School of Medicine, Cracow, Poland

References
1 Guercini F, Acciarresi M, Agnelli G. et al. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 2008; 06: 549-554.
2 Botto N, Spadoni I, Giusti S. et al. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 2007; 38: 2070-2073.
3 Pezzini A, Del Zotto E, Magoni M. et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003; 04: 28-33.
4 de la Red G, Tàssies D, Espinosa G. et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009; 101: 312-316.
5 Rallidis LS, Politou M, Komporozos C. et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
6 Slowik A, Dziedzic T, Pera J. et al. Coagulation factor XIII VaI34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2005; 19: 165-170.
7 Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol 2002; 22: 1058-61.
8 Ariëns RA, Philippou H, Nagaswami C. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
9 Lim BC, Ariëns RA, Carter AM. et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
10 Austin H, Chimowitz MI, Hill HA. et al. Genetics and Stroke in the Young Study Group. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002; 33: 2762-2768.
11 Pezzini A, Grassi M, Zotto ED. et al. Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? Systematic review and meta-analysis. Thromb Haemost 2009; 101: 813-817.
12 Lalouschek W, Schillinger M, Hsieh K. et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 2005; 36: 1405-1409.
13 Rosendaal FR, Doggen CJ, Zivelin A. et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
14 Jood K, Danielson J, Ladenvall C. et al. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost 2008; 06: 897-904.